160 related articles for article (PubMed ID: 18840614)
1. Transcription enhancer factor 3 (TEF3) mediates the expression of Down syndrome candidate region 1 isoform 1 (DSCR1-1L) in endothelial cells.
Liu X; Zhao D; Qin L; Li J; Zeng H
J Biol Chem; 2008 Dec; 283(49):34159-67. PubMed ID: 18840614
[TBL] [Abstract][Full Text] [Related]
2. Requirement of the nuclear localization of transcription enhancer factor 3 for proliferation, migration, tube formation, and angiogenesis induced by vascular endothelial growth factor.
Liu X; Zhao D; James L; Li J; Zeng H
FASEB J; 2011 Apr; 25(4):1188-97. PubMed ID: 21169383
[TBL] [Abstract][Full Text] [Related]
3. Down syndrome candidate region 1 isoform 1 mediates angiogenesis through the calcineurin-NFAT pathway.
Qin L; Zhao D; Liu X; Nagy JA; Hoang MV; Brown LF; Dvorak HF; Zeng H
Mol Cancer Res; 2006 Nov; 4(11):811-20. PubMed ID: 17114339
[TBL] [Abstract][Full Text] [Related]
4. The novel axis of YAP1, transcription enhancer factor 3 and Down Syndrome Candidate Region 1 isoform 1L is a common signaling pathway downstream of several angiogenic factors.
Cui P; Liu X; Zhao K; Hou S; Chen C; Zhao D; Zeng H
Microvasc Res; 2020 May; 129():103955. PubMed ID: 31733305
[TBL] [Abstract][Full Text] [Related]
5. A novel transcriptional complex on the VE-cadherin promoter regulated the downregulation of VE-cadherin in the Down Syndrome Candidate Region 1 isoform 1L-mediated angiogenesis.
Hou S; Niu G; Liu X; Bourbon PM; Zhang D; Cui P; Zhao K; Zhao D; Zeng H
Microvasc Res; 2021 Nov; 138():104209. PubMed ID: 34146582
[TBL] [Abstract][Full Text] [Related]
6. Down Syndrome Candidate Region 1 Isoform 1L regulated tumor growth by targeting both angiogenesis and tumor cells.
Chen C; Cui P; Zhao K; Niu G; Hou S; Zhao D; Zeng H
Microvasc Res; 2022 Mar; 140():104305. PubMed ID: 34958805
[TBL] [Abstract][Full Text] [Related]
7. VEGF selectively induces Down syndrome critical region 1 gene expression in endothelial cells: a mechanism for feedback regulation of angiogenesis?
Yao YG; Duh EJ
Biochem Biophys Res Commun; 2004 Aug; 321(3):648-56. PubMed ID: 15358155
[TBL] [Abstract][Full Text] [Related]
8. Down syndrome candidate region 1-like 1 (DSCR1-L1) mimics the inhibitory effects of DSCR1 on calcineurin signaling in endothelial cells and inhibits angiogenesis.
Gollogly LK; Ryeom SW; Yoon SS
J Surg Res; 2007 Sep; 142(1):129-36. PubMed ID: 17610901
[TBL] [Abstract][Full Text] [Related]
9. Down syndrome critical region protein 1 (DSCR1), a novel VEGF target gene that regulates expression of inflammatory markers on activated endothelial cells.
Hesser BA; Liang XH; Camenisch G; Yang S; Lewin DA; Scheller R; Ferrara N; Gerber HP
Blood; 2004 Jul; 104(1):149-58. PubMed ID: 15016650
[TBL] [Abstract][Full Text] [Related]
10. Nuclear localization of TEF3-1 promotes cell cycle progression and angiogenesis in cancer.
Teng K; Deng C; Xu J; Men Q; Lei T; Di D; Liu T; Li W; Liu X
Oncotarget; 2016 Mar; 7(12):13827-41. PubMed ID: 26885617
[TBL] [Abstract][Full Text] [Related]
11. Depolarization of neural cells induces transcription of the Down syndrome critical region 1 isoform 4 via a calcineurin/nuclear factor of activated T cells-dependent pathway.
Cano E; Canellada A; Minami T; Iglesias T; Redondo JM
J Biol Chem; 2005 Aug; 280(33):29435-43. PubMed ID: 15975916
[TBL] [Abstract][Full Text] [Related]
12. Secretion of Down Syndrome Critical Region 1 Isoform 4 in Ischemic Retinal Ganglion Cells Displays Anti-Angiogenic Properties Via NFATc1-Dependent Pathway.
Xu Y; Yang B; Hu Y; Lu L; Lu X; Wang J; Shu Q; Cheng Q; Yu S; Xu F; Huang J; Liang X
Mol Neurobiol; 2017 Oct; 54(8):6556-6571. PubMed ID: 27734335
[TBL] [Abstract][Full Text] [Related]
13. RTEF-1, a novel transcriptional stimulator of vascular endothelial growth factor in hypoxic endothelial cells.
Shie JL; Wu G; Wu J; Liu FF; Laham RJ; Oettgen P; Li J
J Biol Chem; 2004 Jun; 279(24):25010-6. PubMed ID: 15073166
[TBL] [Abstract][Full Text] [Related]
14. Characterization of the transcriptional activation domains of human TEF3-1 (transcription enhancer factor 3 isoform 1).
Qiao C; Jiang Y; Deng C; Huang Z; Teng K; Chen L; Liu X
Arch Biochem Biophys; 2015 Mar; 569():54-61. PubMed ID: 25687649
[TBL] [Abstract][Full Text] [Related]
15. Down syndrome candidate region 1,a downstream target of VEGF, participates in endothelial cell migration and angiogenesis.
Iizuka M; Abe M; Shiiba K; Sasaki I; Sato Y
J Vasc Res; 2004; 41(4):334-44. PubMed ID: 15263820
[TBL] [Abstract][Full Text] [Related]
16. Restoration of DSCR1 to disomy in the trisomy 16 mouse model of Down syndrome does not correct cardiac or craniofacial development anomalies.
Lange AW; Rothermel BA; Yutzey KE
Dev Dyn; 2005 Jul; 233(3):954-63. PubMed ID: 15906378
[TBL] [Abstract][Full Text] [Related]
17. A single extra copy of Dscr1 improves survival of mice developing spontaneous lung tumors through suppression of tumor angiogenesis.
Shin J; Lee JC; Baek KH
Cancer Lett; 2014 Jan; 342(1):70-81. PubMed ID: 24051307
[TBL] [Abstract][Full Text] [Related]
18. DSCR1, overexpressed in Down syndrome, is an inhibitor of calcineurin-mediated signaling pathways.
Fuentes JJ; Genescà L; Kingsbury TJ; Cunningham KW; Pérez-Riba M; Estivill X; de la Luna S
Hum Mol Genet; 2000 Jul; 9(11):1681-90. PubMed ID: 10861295
[TBL] [Abstract][Full Text] [Related]
19. Targeted deletion of the calcineurin inhibitor DSCR1 suppresses tumor growth.
Ryeom S; Baek KH; Rioth MJ; Lynch RC; Zaslavsky A; Birsner A; Yoon SS; McKeon F
Cancer Cell; 2008 May; 13(5):420-31. PubMed ID: 18455125
[TBL] [Abstract][Full Text] [Related]
20. Telomerase mediates vascular endothelial growth factor-dependent responsiveness in a rat model of hind limb ischemia.
Zaccagnini G; Gaetano C; Della Pietra L; Nanni S; Grasselli A; Mangoni A; Benvenuto R; Fabrizi M; Truffa S; Germani A; Moretti F; Pontecorvi A; Sacchi A; Bacchetti S; Capogrossi MC; Farsetti A
J Biol Chem; 2005 Apr; 280(15):14790-8. PubMed ID: 15687494
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
